Related Experiment Videos
Chromatographically purified vancomycin: therapy of serious infections caused by Staphylococcus aureus and other
1Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Abstract:
Fourteen patients with serious infections caused by Staphylococcus aureus and other gram-positive bacteria were prospectively treated with chromatographically purified vancomycin in an open-label, nonrandomized study, between December 1986 and June 1987. Five patients were excluded from the evaluation of efficacy. Among the nine evaluable patients, cure was achieved in six patients--a success rate of 67%. One patient had a relapse of osteomyelitis, and cultures of draining pus were positive for oxacillin-resistant S aureus within three weeks after the discontinuation of vancomycin therapy. One patient failed to respond to vancomycin therapy for S aureus-induced endocarditis, meningitis, and osteomyelitis; in another patient, the treatment failed to reverse the course of S aureus septicemia. No serious drug toxicity, for example, nephrotoxicity, was encountered in any patient. One patient (7%) experienced mild ototoxicity. Four patients (29%) had mild phlebitis, two patients (14%) had a transiently positive Coombs' test, and one patient (7%) had a "red neck syndrome" and "pain and spasm syndrome." Chromatographically purified vancomycin is an effective antibiotic in the treatment of serious infections caused by susceptible gram-positive bacteria. Some minor side effects of vancomycin may not be due to impurities in the preparation but rather to the vancomycin itself.
Insights
Chromatographically purified vancomycin effectively treated serious gram-positive bacterial infections in 67% of patients. Minor side effects were observed, but no serious toxicity like nephrotoxicity occurred, suggesting vancomycin
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Serious infections caused by Staphylococcus aureus and other gram-positive bacteria pose significant treatment challenges.
- Vancomycin is a critical antibiotic for managing infections caused by resistant gram-positive pathogens.
- The efficacy and safety profile of chromatographically purified vancomycin needed further clinical evaluation.
Purpose of the Study:
- To assess the efficacy and safety of chromatographically purified vancomycin in patients with serious gram-positive bacterial infections.
- To determine the cure rate and identify adverse events associated with this vancomycin preparation.
Main Methods:
- Prospective, open-label, nonrandomized study.
- 14 patients with serious infections caused by Staphylococcus aureus and other gram-positive bacteria were treated.
- Efficacy was evaluated in 9 patients, with cure rates and adverse events meticulously recorded.
Main Results:
- A 67% cure rate was achieved in the 9 evaluable patients.
- One patient experienced a relapse of osteomyelitis due to oxacillin-resistant S. aureus.
- Minor side effects included mild ototoxicity (7%), mild phlebitis (29%), transiently positive Coombs' test (14%), and "red neck syndrome" (7%). No serious toxicity was observed.
Conclusions:
- Chromatographically purified vancomycin demonstrates effectiveness in treating serious infections caused by susceptible gram-positive bacteria.
- Observed minor side effects may be intrinsic to vancomycin rather than preparation impurities.
- Further research into vancomycin's side effect profile is warranted.